This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Biogen Idec. 

Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader with leading products and capabilities in oncology, neurology and immunology, is committed to transforming scientific discovery into advances in healthcare. The company's core capabilities include drug discovery, research, development, biomanufacturing, and a global commercial infrastructure.
In June 2003, Biogen and IDEC Pharmaceuticals announced their agreement to merge. This merger was finalized in November 2003, creating Biogen Idec, the third-largest biotechnology company in the world. The company is a NASDAQ-traded firm listed under the symbol BIIB.

Product overview

• RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL).
• AVONEX® (Interferon beta 1-a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS)
• Zevalin- cancer therapy for patients with non-hodgkin's lymphoma
• Amevive- moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.